Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156403 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00156403 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 8 participants.
The verdict
NCT00156403, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot study is a feasibility, safety, and preliminary benefits study to look at whether giving the calcium channel blocker amlodipine to people with hereditary pancreatitis as a prophylactic measure can reduce the inflammatory process in the pancreas.
Interventions
- DRUG amlodipine (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-08 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00156403
The ClinicalTrials.gov registry entry for NCT00156403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which amlodipine (drug) is the first listed.
NCT00156403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00156403 about?
NCT00156403 is a clinical study titled "A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis". This pilot study is a feasibility, safety, and preliminary benefits study to look at whether giving the calcium channel blocker amlodipine to people with hereditary pancreatitis as a prophylactic measure can reduce the inflammatory process in the pancreas.
What is the current status of trial NCT00156403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2005-08. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00156403?
The interventions under investigation include: amlodipine (drug) (DRUG).
Who is sponsoring clinical trial NCT00156403?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.